JAN 12, 2016 9:00 PM PST

Gene that stops tumors may spread colorectal cancer

A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer.

The discovery may lay the foundation for new colorectal cancer treatments.
 
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States.

“The gene known as Sprouty2 has previously been shown to protect against metastasis, or the spreading of cancer to other parts of the body, in breast, prostate, and liver cancer,” says Sharad Khare, associate professor of research in the University of Missouri School of Medicine’s Division of Gastroenterology and Hepatology and lead author of the study that is published in the journal Oncogene.

“However, our recent molecular studies found that this gene may actually help promote metastasis instead of suppress it.”

For more than three years, researchers have studied Sprouty2 in cancer cell models, mouse models, and human biopsy samples. Using different molecular methods, the researchers found that the gene functions differently in colorectal cancer than in other types of cancers.

Sprouty2 is known to block molecular circuits to prevent cancer cells from growing and spreading to other parts of the body. However, in colorectal cancer, Sprouty2 may increase the metastatic ability of cancer cells instead of suppress it. Khare believes this occurs when the gene is up-regulated, or supercharged.

Cancer deaths attributed to colorectal cancer are mainly due to tumor recurrence and metastasis to other organs. Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, according to the American Cancer Society. It’s estimated that the lifetime risk of developing colorectal cancer is about 1 in 20.

“This finding is a very significant step in our understanding of metastasis in colorectal cancer, but it’s important to note that we believe this phenomenon may occur in only a subset of colorectal cancer patients,” Khare says.

“We don’t yet know why this is the case, but we hope to determine if there is a correlation between the up-regulation of this gene and the life expectancy of patients with colorectal cancer. Future studies will help us understand who may be at risk, and ultimately, if personalized treatments can be planned to target this gene.”

The National Institutes of Health, a Veterans Affairs Merit Award, the MU Research Board Award and MU School of Medicine Bridge funded the work. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

This article was originally published on futurity.org
About the Author
MS
Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
AUG 18, 2022
Cancer
Why are Men More Prone to Cancer than Women?
AUG 18, 2022
Why are Men More Prone to Cancer than Women?
The overall risk of developing cancer is about the same for men and women (40.2% and 38.5%, respectively).  However ...
SEP 11, 2022
Microbiology
Using Yeast Cells to Make a Cancer Treatment
SEP 11, 2022
Using Yeast Cells to Make a Cancer Treatment
Vinblastine and vincristine are both common chemotherapies that are used to treat several types of cancer. The drugs sto ...
SEP 26, 2022
Cancer
Clinical Trial Suggests Oncolytic Virus Effective in Combination with Immune Checkpoint Inhibition
SEP 26, 2022
Clinical Trial Suggests Oncolytic Virus Effective in Combination with Immune Checkpoint Inhibition
One type of cancer immunotherapy, called oncolytic viral therapy, works by infecting cancer cells with a specific virus. ...
OCT 18, 2022
Immunology
Cell Adhesion Molecules in Immune and Cancer Therapy
OCT 18, 2022
Cell Adhesion Molecules in Immune and Cancer Therapy
Introduction The immune system plays a dual role in inflammation and cancer development. Immune system effector cells ra ...
NOV 02, 2022
Clinical & Molecular DX
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
NOV 02, 2022
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
Ovarian cancer is a complex disease resulting from mutated cells in the ovaries. As the cells multiply, they can invade ...
DEC 08, 2022
Cancer
Could a Drug for Parkinson's Disease Reduce the Side Effects of Chemotherapy?
DEC 08, 2022
Could a Drug for Parkinson's Disease Reduce the Side Effects of Chemotherapy?
Chemotherapies, drugs used to fight cancer by killing tumor cells or preventing them from growing and dividing, remain s ...
Loading Comments...